Abstract
Pigmentation of the oral mucosa can indicate a wide range of lesions or conditions. Some drugs are associated with pigmented lesions of oral cavity. Imatinib mesylate (Gleevec(®)) is a protein inhibitor used in the management of several hematological malignancies associated with dermatological side effects, like hyperpigmentation. We report the case of a 38-year-old male post-HSCT patient who had been using imatinib mesylate for over 5 years and presented with blue pigmentation on the hard palate, the left side of the nose and both ear lobes. The differential diagnosis of hyperpigmented lesions in the oral mucosa is also presented.
Copyright © 2011 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antineoplastic Agents / adverse effects*
-
Benzamides
-
Ear Diseases / chemically induced
-
Ear, External / drug effects
-
Facial Dermatoses / chemically induced
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Hyperpigmentation / chemically induced*
-
Imatinib Mesylate
-
Male
-
Maxillary Diseases / chemically induced*
-
Neoplasms, Second Primary / pathology
-
Neurofibromatosis 1 / pathology
-
Nose Diseases / chemically induced
-
Palate, Hard / drug effects*
-
Piperazines / adverse effects*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Pyrimidines / adverse effects*
-
Tissue Conditioning, Dental
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate
-
Protein-Tyrosine Kinases